Evolus to Participate in Two Upcoming Investor Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/19/2026

1. NVDA
2. KLAR
3. SPY
4. HD
5. AMLX

6. METC
7. DOO
8. ARGX
9. INFQ
10. SNOW

Get Alerts EOLS Hot Sheet

Price: $8.18 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

IRVINE, Calif., June 14, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (“Evolus”) (NASDAQ: EOLS), a premiere aesthetics company, announced today that members of management will be participating in two upcoming investor conferences in New York, NY.


			Event:		Cantor 2018 Dermatology & Aesthetics Summit
			Panel:		Novel Aesthetic Dermatology Drugs and Devices for Unmet Needs
			Date:		Tuesday, June 19, 2018
			Time:		12:00 p.m. ET
			Location:		The Westin New York Grand Central, New York


			Event:		JMP Securities Life Sciences Conference
			Date:		Wednesday, June 20, 2018
			Time:		9:00 a.m. ET
			Location:		The St. Regis, New York

An audio webcast of the Company’s presentation at the JMP Securities Life Sciences Conference will be available on the investor relations section of Evolus’ website at investors.evolus.com. Replays of the webcast will be available for 90 days after the date of the presentation.

About Evolus, Inc.

Evolus is a premiere aesthetics company focused on providing physicians and their patients with expanded choices in aesthetic treatments and procedures. Evolus’ lead product candidate DWP-450, also known by the chemical name prabotulinumtoxinA, is a 900 kDa purified botulinum toxin type A complex that is being evaluated for the treatment of moderate to severe glabellar lines in adult patients.

Evolus Contacts:

Investor Contact:Brian Johnston, The Ruth Group Tel: +1 646-536-7028Email: [email protected]

Media Contact:Kirsten Thomas, The Ruth GroupTel: +1-508-280-6592Email: [email protected]